New data for Roche ’s Hemlibra reinforce safety profile in people with haemophilia A
Basel, 19 July 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced results from the final analysis of the phase IIIb STASEY study, which confirm the favourable safety profile of Hemlibra ® (emicizumab), consistent with the phase III HAVEN clinical programme.1,2,3,4 In the analysis, no new safety signals were identified with longer-term Hemlibra treatment in adults and adolescents with haemophilia A with inhibitors to factor VIII, the clotting protein that is missing or defective in people with haemophilia A. The data were presented at the virtual International Society on Thrombosis and Haemostasis (ISTH) 2021 Congre...
Source: Roche Investor Update - July 19, 2021 Category: Pharmaceuticals Source Type: news
Roche to present new data at the ISTH 2021 Congress highlighting long-standing commitment to advancing haemophilia A standard of care
Basel, 02 July 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new data from its haemophilia A clinical programme will be presented at the virtual International Society on Thrombosis and Haemostasis (ISTH) 2021 Congress, from 17-21 July 2021. Data will include the final analysis from the phase IIIb STASEY study of Hemlibra ® (emicizumab) and updated data from the phase I/II study of SPK-8011, an AAV-based gene therapy in development by Spark Therapeutics (a member of the Roche Group).1,2 (Source: Roche Media News)
Source: Roche Media News - July 2, 2021 Category: Pharmaceuticals Source Type: news
Roche to present new data at the ISTH 2021 Congress highlighting long-standing commitment to advancing haemophilia A standard of care
Basel, 02 July 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new data from its haemophilia A clinical programme will be presented at the virtual International Society on Thrombosis and Haemostasis (ISTH) 2021 Congress, from 17-21 July 2021. Data will include the final analysis from the phase IIIb STASEY study of Hemlibra ® (emicizumab) and updated data from the phase I/II study of SPK-8011, an AAV-based gene therapy in development by Spark Therapeutics (a member of the Roche Group).1,2 (Source: Roche Investor Update)
Source: Roche Investor Update - July 2, 2021 Category: Pharmaceuticals Source Type: news
Recombinant FVIII appears to be cost effective for severe haemophilia A in the USA
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - July 1, 2021 Category: Drugs & Pharmacology Source Type: news
Management costs and economic burden of haemophilia A high in France
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - July 1, 2021 Category: Drugs & Pharmacology Source Type: news
UniQure stock falls after news of new CFO, acquisition, and new trial data
Shares of UniQure N.V., a Netherlands-based biotech with U.S. headquarters in Lexington, fell on Tuesday after three very different announcements involving a new top executive, an acquisition and new trial data.
UniQure (Nasdaq: QURE) share prices were hovering around $30 as of 2:45 p.m., a decrease of more than 8%, giving the company a market cap of $1.4 billion.
The company earlier in the day announced positive topline data from a Phase 3 study of its hemophilia B drug, etranacogene dezaparvovec,… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - June 22, 2021 Category: American Health Authors: Rowan Walrath Source Type: news
Up close and personal – The Dr. Kevin Williams story
From a young age, Dr. Kevin Williams looked to his father as a role model. Back in 1952, his father became the third African American physician in Baton Rouge, Louisiana, despite barriers and discrimination faced by Black professionals in the medical field. “It was a different time,” says Kevin. “When my father first opened his practice, none of the hospitals would give him admitting privileges.” At his office, Kevin ’s father saw patients on a first come, first served basis. Patients in the area were so eager to see him that they started lining up at 4 o’clock each morning, even creating their own sign-...
Source: EyeForPharma - June 7, 2021 Category: Pharmaceuticals Authors: Jill Donahue Source Type: news
Up close and personal – The Dr. Kevin Williams story
From a young age, Dr. Kevin Williams looked to his father as a role model. Back in 1952, his father became the third African American physician in Baton Rouge, Louisiana, despite barriers and discrimination faced by Black professionals in the medical field. “It was a different time,” says Kevin. “When my father first opened his practice, none of the hospitals would give him admitting privileges.” At his office, Kevin ’s father saw patients on a first come, first served basis. Patients in the area were so eager to see him that they started lining up at 4 o’clock each morning, even creating their own sign-...
Source: EyeForPharma - June 7, 2021 Category: Pharmaceuticals Authors: Jill Donahue Source Type: news
Health Costs Over 25 Times Higher for Patients With Hemophilia B Health Costs Over 25 Times Higher for Patients With Hemophilia B
As the burden of hemophilia B in patients increases from mild to severe forms of the disease, the already high economic cost of treatment rises significantly, according to a large retrospective database study.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - May 12, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Namibia: Mother and Sons' Journey With Haemophilia
[Namibian] Joys of a mother come from seeing her sons growing into men, with the bruises and all that come from engaging other boys of their age, but this was not the case with Veronica Mayiji. (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - April 21, 2021 Category: African Health Source Type: news
B cell activating factor possible key to hemophilia immune tolerance
(Indiana University School of Medicine) A group of scientists have just made a key discovery that could prevent and eradicate immune responses that lead to treatment failure in about one-third of people with severe hemophilia A. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 19, 2021 Category: International Medicine & Public Health Source Type: news
CHOP-led research study identifies key target in treatment-resistant hemophilia A
(Children's Hospital of Philadelphia) Researchers at Children's Hospital of Philadelphia (CHOP) have identified a key target that may be responsible for treatment failure in about 30% of patients with hemophilia A. The target, known as B cell activating factor (BAFF), appears to promote antibodies against and inhibitors of the missing blood clotting factor that is given to these patients to control their bleeding episodes. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 15, 2021 Category: International Medicine & Public Health Source Type: news
BioMarin Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to Valoctocogene Roxaparvovec, Investigational Gene Therapy for Hemophilia A
RMAT Designation Granted by FDA During Bleeding Disorders Awareness Month
SAN RAFAEL, Calif., March 8, 2021 -- (Healthcare Sales & Marketing Network) -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that the U.S. Food and Drug Administrat... Biopharmaceuticals, FDA BioMarin, Valoctocogene Roxaparvovec, Hemophilia (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 8, 2021 Category: Pharmaceuticals Source Type: news
Fidelis Specialty Pharmacy Selects Citus Health to Enable Real-Time...
Innovative specialty pharmacy provider for hemophiliac and bleeding disorder patients to implement Citus Health’s HIPAA-compliant digital health solution suite to improve patient and staff...(PRWeb March 04, 2021)Read the full story at https://www.prweb.com/releases/fidelis_specialty_pharmacy_selects_citus_health_to_enable_real_time_virtual_patient_communications_and_faster_collection_of_key_patient_data/prweb17770242.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - March 4, 2021 Category: Pharmaceuticals Source Type: news
Mission 2030: Bayer ’s quest for climate neutrality
One hundred times per week. That ’s how often specially trained Bayer team members used to clean certain stainless-steel vessels as part of a six-month-long drug manufacturing process. The medicine in question is a biotech treatment for people with a rare blood-clotting disorder. The vessels held buffering agents, solutions that are used in the purification process of making Factor VIII, the protein missing in people living with hemophilia A. Cleaning each vessel required significant amounts of… (Source: bizjournals.com Health Care News Headlines)
Source: bizjournals.com Health Care News Headlines - February 26, 2021 Category: Health Management Authors: Lauren Lawley Head Source Type: news
